

BioGaia initiates investigative study in type 2 diabetics

BioGaia has initiated an investigative study in type 2 diabetics together with Gothia Forum for Clinical Research at Sahlgrenska University Hospital in Gothenburg in collaboration with Sahlgrenska Center for Cardiovascular and Metabolic Research.

Based on encouraging findings after supplementation of BioGaia's probiotic strain *Lactobacillus reuteri* Protectis in patients with type 2 diabetes in an earlier pilot study, this double-blind, placebo-controlled study will examine the effects of *Lactobacillus reuteri* Protectis supplementation on blood glucose control over a 12 week period. The study will address both clinical outcome parameters as well as attempting to define potential mechanistic explanations for the effects seen.

BioGaia is issuing this press release, as the study will soon become public on www.clinicaltrials.gov following approval from the ethical committee and according to requirements of the company. More details regarding the study can be found on this web site.

– We are at an early stage in the development of products in this potentially interesting new area for BioGaia. Type 2 diabetes is a huge and growing problem all over the world, says Peter Rothschild, President, BioGaia.

For additional information please contact

Peter Rothschild, President, telephone: +46 8 555 293 00

Eamonn Connolly, Senior Vice President Research: +46 8 555 293 00

Latest press releases from BioGaia

2012-05-09 Annual General Meeting of BioGaia

2012-05-08 Interim report 1 January-31 March 2012

2012-04-17 BioGaia signs exclusive distribution agreement for its probiotic drops and tablets in Taiwan

BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 14 May 2012, 09:00 am CET.

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium *Lactobacillus reuteri* which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com